Type to search

Clinical Trials Diseases Industry News News Oncology Partnerships

Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer

Share
Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer | Pharmtech Focus

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced it has entered into a clinical trial collaboration agreement with Merck.

Under this collaboration, Hummingbird will evaluate the safety, tolerability, and anti-tumor activity of its novel anti-VISTA antibody, HMBD-002, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and other cancers with high VISTA expression. HMBD-002 is anticipated to enter a Phase 1 clinical trial in 2021.

VISTA is a co-inhibitory immune checkpoint receptor that is involved in suppressing an anti-tumor immune response. Overexpression of VISTA in the immune cells in tumors has also been associated with acquired resistance to other checkpoint therapies, such as anti-PD1 therapies. TNBC and NSCLC were identified as priority indications for clinical investigation based on the unmet need for new treatment options and widespread expression of VISTA in these tumor types. HMBD-002 is the only IgG4 isotype anti-VISTA antibody currently in development. It is precisely engineered to bind to VISTA at a specific site that is predicted to be essential for ligand-binding and function, and thereby inhibits VISTA by neutralizing its immunosuppressive activity without depleting other VISTA expressing cells that play many important roles in the immune system. Preclinical studies have demonstrated potent anti-tumor activity both as single agent and in combination with PD-1 therapy.

“Our preclinical studies have shown that VISTA in combination with PD-1 therapy can enhance anti-tumor activity. We look forward to initiating clinical trials for HMBD-002 as we aim to develop new treatment options for patients who do not respond to existing therapies,” said Piers Ingram, Chief Executive Officer and co-founder of Hummingbird.

Tags:

People in this post:

Companies in this post:

You Might also Like

Related Stories

Next Up